PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

46,012 stories, page 675 of 767

Advanced search
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT05368207: Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT05189223: A Brief Values Intervention to Support Veterans in Early Buprenorphine Treatment

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT04181827: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT04010877: Multiple CAR-T Cell Therapy Targeting AML

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT03586661: Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT03194906: Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT00520975: Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source
🇺🇸Researchclinicaltrials.govTier 1 · Trial registry

NCT00231400: Pompe Disease Registry Protocol

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

How Teva’s Ecopipam Tourette NDA and AUSTEDO Data Will Impact Teva Pharmaceutical Industries (TEVA) Investors

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Did New VOXZOGO and BMN 333 Data Just Shift BioMarin Pharmaceutical's (BMRN) Investment Narrative?

simplywall.stOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Another of Pfizer's Seagen-sourced ADCs stumbles in the clinic

FirstWord PHARMAOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Majority of Americans Value Women’s Safety over Ease of Abortion Drug Access

The Washington StandOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

Investing News NetworkOriginal source
🌍discoverynews.google.comTier 2 · Trade media

FDA launches pilot to speed drug testing as China surges in biotech race

FirstWord PHARMAOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

UPS adds 27 cold transfer facilities for pharmaceutical shipping

FreightWavesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Chart Master: Is it time to buy biotech?

CNBCOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Serratiopeptidase Pharmaceutical Enzyme Market Growth Forecast to 2035: Bioprocessing and Therapeutic Demand Accelerate - News and Statistics

IndexBoxOriginal source
🌍Mediaechonous.comTier 2 · Direct publisher

The Best Bladder Scanners in 2026: Comparison, Reviews, & Buyer’s Guide

EchoNousOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Biotech rivalry between US, China intensifies: Poll

Anadolu AjansıOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Biotech firms add financial leaders in 2026

BioXconomyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

New Paper | Beyond the Biotech Race — Right-Sizing U.S.-China Competition in a Human-Centered Industry

Asia SocietyOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Reuters Health News Summary

DevdiscourseOriginal source
🌍Regulatorycssp.gob.svTier 1 · Regulatory source

Curso de Legislación Laboral aplicada a la Regencia de Servicios de Salud

Consejo Superior de Salud Pública (El Salvador)Original source
🌍discoverynews.google.comTier 3 · Aggregated media

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Business WireOriginal source
🌍Industryzevra.comTier 1 · Company source

Arimoclomol in infants with Niemann-Pick disease type C: Results from the phase 2/3 open-label pediatric substudy

Zevra TherapeuticsOriginal source
🌍Industryinvestors.vivani.comTier 1 · Company source

Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

Vivani MedicalOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Launches Effort to Accelerate Drug Trials

NewsmaxOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

AJMCOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

China closing in but US leads in biotech quality, commercial reach, survey finds

ReutersOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

AbbVie Acquires Apogee Therapeutics for $10.9 Billion | PharmExec

Pharmaceutical ExecutiveOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Krystal Biotech (KRYS) Is Up 7.2% After Institutional Ownership Surges To Sector-Leading Levels

simplywall.stOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Insilico lands potential $2.5bn AI biotech partnership

Life Sciences Intellectual Property ReviewOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Biotech Spotlight: Innovative Laboratory Systems

SiouxFalls.BusinessOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

U.S. to Speed Up Early Drug Research to Better Compete With China

WSJOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA and USDA issue major recalls over safety risks

MSNOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Innovent's Trispecific Antibody IBI3003 Advances Into Phase 3 for Relapsed or Refractory Multiple Myeloma

BioPharm InternationalOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Novartis lays off 60 workers at Flatiron biotech after $1.4B acquisition

Crain's New York BusinessOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Bulletin: Phase 3 Clinical Trial Success for Smart Watch Epilepsy App

Medical News BulletinOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

The New EU Pharmaceutical Legislation: Key Points for Deal Teams

Morgan LewisOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Recon: AbbVie forges $10.9 billion deal with Apogee; US FDA changes tack on Regenxbio's rare disease gene therapy

RAPS.orgOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA’s Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters

JD SupraOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

USTR Launches Section 301 Investigation into Germany’s Underpayment for Pharmaceutical Products

thompsonhinesmartrade.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

This Biotech Could Become a ‘Sleeper’ Hit

TheStreet ProOriginal source
🌍Regulatorytransceleratebiopharmainc.comTier 1 · Regulatory source

Enough, already: the problem with clinical trial data collection

TransCelerate BioPharmaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA launches drug trial overhaul and issues recall

MSNOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

HHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials

HHS.govOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA launches study of abortion pill safety, WSJ reports

MSNOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Pharma goes on a spending spree, snapping up biotechs in a hurry

statnews.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Issues Nationwide Recall for Popular Cough Drops - Here's the Full List

AOL.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Oppenheimer raises Definium Therapeutics stock price target on trial data By Investing.com

Investing.com South AfricaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical Majors Cut Investments in Germany

Industrial Info ResourcesOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

AbbVie paying $10.9B to buy Waltham biotech

NBC BostonOriginal source
🌍discoverynews.google.comTier 2 · Trade media

Sanofi’s R&D head exits, with AI biotech Xaira’s exec stepping in

BioSpaceOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

To Prevent the Burn: The FDA Finally Approves a New Sunscreen

American Council on Science and HealthOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Oppenheimer raises Definium Therapeutics stock price target on trial data

Investing.comOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Recall: Is your blood pressure medication affected?

Rolling OutOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat Epilepsy

BenzingaOriginal source
🌍discoverynews.google.comTier 2 · Trade media

FDA to launch pilot program to speed up early-stage clinical trials

statnews.comOriginal source
🇺🇰Researchsphr.nihr.ac.ukTier 2 · Direct publisher

An international conversation on child health equity: Reflections from INRICH 2026

NIHR School for Public Health ResearchOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies

AJMCOriginal source